Paclitaxel 300 M g Txl Oncovan

A qualified oncology team administers it as an intravenous infusion after premedication to reduce allergic reactions.

Oncovan Paclitaxel 300mg Injection Ingredients and Usage

Oncovan Paclitaxel 300mg Injection contains paclitaxel, a taxane belonging to the antimicrotubule anticancer drug class. Oncologists prescribe it as first line therapy for ovarian carcinoma, usually combined with cisplatin, and as second line treatment after platinum based therapy fails.

Oncovan Paclitaxel 300mg Injection also treats node positive breast cancer as adjuvant therapy, non small cell lung cancer, and AIDS related Kaposi's sarcoma. A specialist experienced in chemotherapy administration must supervise every infusion.

How Does Oncovan Paclitaxel 300mg Injection Work?

Paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes the resulting structure by preventing depolymerization. Microtubules normally disassemble and reassemble to allow cell division to proceed.

By locking microtubules in place, Oncovan Paclitaxel 300mg Injection blocks the normal dynamic reorganization needed for mitosis. This arrests cancer cells during cell division and triggers cell death, slowing tumor growth across multiple cancer types.

Oncovan Paclitaxel 300mg Injection Side Effects

Oncovan Paclitaxel 300mg Injection commonly causes blood count changes and nerve related side effects. Close monitoring during and after infusion is standard practice.

• Low white blood cell count, raising infection risk

• Peripheral neuropathy, numbness or tingling in hands and feet

• Hair loss

• Joint and muscle pain

• Nausea and vomiting

• Fatigue

• Mouth sores

Warnings

• Oncovan Paclitaxel 300mg Injection can cause severe hypersensitivity reactions, including fatal anaphylaxis, even after standard premedication with corticosteroids, antihistamines, and H2 blockers.

• Do not restart treatment in patients who have experienced a severe hypersensitivity reaction to paclitaxel.

• Avoid use in patients with a baseline neutrophil count below 1,500 cells per cubic millimeter, since this raises the risk of serious infection.

• Oncovan Paclitaxel 300mg Injection is not recommended in pregnancy, since it may harm an unborn baby; men and women should use reliable contraception during treatment.

• Avoid aspirin or aspirin containing products unless specifically approved by the treating doctor.

• Use with caution in patients with impaired liver or kidney function, since dose adjustment may be required.

• Avoid alcohol during treatment, and report any signs of infection, unusual bruising, or bleeding to the doctor immediately.

Oncovan Paclitaxel 300mg Injection Storage Conditions

Store unopened vials of Oncovan Paclitaxel 300mg Injection between 20°C and 25°C, protected from light. Keep the vial in its original carton until immediately before use, and avoid exposure to direct sunlight or excess heat. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.